###begin article-title 0
###xml 27 31 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 105 110 <span type="species:ncbi:9606">human</span>
ErbB2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in 20% to 30% of human breast cancer cases and forms oncogenic signalling complexes when dimerised to ErbB3 or other EGFR family members.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 39 43 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
###xml 139 143 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 152 167 <span type="species:ncbi:10090">transgenic mice</span>
We crossed mouse mammary tumour virus (MMTV)-myr-Akt1 transgenic mice (which express constitutively active Akt1 in the mammary gland) with MMTV-c-ErbB2 transgenic mice to evaluate the role of Akt1 activation in ErbB2-induced mammary carcinoma using immunoblot analysis, magnetic resonance spectroscopy and histological analyses.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 13 17 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 27 31 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 87 91 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
Bitransgenic MMTV-c-ErbB2, MMTV-myr-Akt1 mice develop mammary tumours twice as fast as MMTV-c-ErbB2 mice. The bitransgenic tumours were less organised, had more mitotic figures and fewer apoptotic cells. However, many bitransgenic tumours displayed areas of extensive necrosis compared with tumours from MMTV-c-ErbB2 mice. The two tumour types demonstrate dramatically different expression and activation of EGFR family members, as well as different metabolic profiles. c-ErbB2 tumours demonstrate overexpression of EGFR, ErbB2, ErbB3 and ErbB4, and activation/phosphorylation of both ErbB2 and ErbB3, underscoring the importance of the entire EGFR family in ErbB2-induced tumourigenesis. Tumours from bitransgenic mice overexpress the myr-Akt1 and ErbB2 transgenes, but there was dramatically less overexpression and phosphorylation of ErbB3, diminished phosphorylation of ErbB2, decreased level of EGFR protein and undetectable ErbB4 protein. There was also an observable attenuation in a subset of tyrosine-phosphorylated secondary signalling molecules in the bitransgenic tumours compared with c-ErbB2 tumours, but Erk was activated/phosphorylated in both tumour types. Finally, the bitransgenic tumours were metabolically more active as indicated by increased glucose transporter 1 (GLUT1) expression, elevated lactate production and decreased intracellular glucose (suggesting increased glycolysis).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 32 36 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
Expression of activated Akt1 in MMTV-c-ErbB2 mice accelerates tumourigenesis with a reduced requirement for signalling through the EGFR family, as well as a reduced requirement for a subset of downstream signaling molecules with a metabolic shift in the tumours from bitransgenic mice. The reduction in signalling downstream of ErbB2 when Akt is activated suggest a possible mechanism by which tumour cells can become resistant to ErbB2-targeted therapies, necessitating therapies that target oncogenic signalling events downstream of ErbB2.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 782 783 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 784 785 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1211 1212 1211 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 342 357 <span type="species:ncbi:10090">transgenic mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 645 660 <span type="species:ncbi:10090">transgenic mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 853 858 <span type="species:ncbi:10090">mouse</span>
###xml 881 885 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 911 915 <span type="species:ncbi:10090">mice</span>
###xml 1204 1209 <span type="species:ncbi:10090">mouse</span>
The ErbB2/Neu/HER2 oncogene is amplified and overexpressed in 20% to 30% of human breast cancer cases, and expression of ErbB2 is associated with aggressive metastatic tumour behaviour, decreased time to clinical relapse and poor prognosis [1,2]. The importance of c-ErbB2 in mammary tumourigenesis was further established through a study of transgenic mice that expressed either activated ErbB2 (Neu-NT) [3,4] or non-activated c-ErbB2 [5,6]. Activated ErbB2-induced tumours in male and female mice have an average time to tumour appearance of 114 and 89 days, respectively [3], while expression of non-activated c-ErbB2 in the mammary gland of transgenic mice resulted in tumour formation in female mice in 150 to 300 days, with the latency depending on the founder line examined [5,6]. The most extensively investigated transgenic line to date is the mouse mammary tumour virus (MMTV)-c-ErbB2 line 202 female mice in which adenocarcinomas appear with an average latency of 205 days [6]. Overexpression of c-ErbB2 mRNA and protein, elevated c-ErbB2 kinase activity and increased tyrosine phosphorylation of cellular proteins was observed in tumour tissue, but not in normal mammary tissue from the same mouse [6].
###end p 11
###begin p 12
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Protein levels of ErbB3 and tyrosine phosphorylation of ErbB3 are increased in mammary tumours from transgenic mice expressing activated ErbB2 (Neu-DL) [7], suggesting that ErbB2 and ErbB3 function as an oncogenic unit [8,9]. Holbro et al. [9] demonstrated that loss of either functional ErbB2 or ErbB3 results in a loss of tumour cell proliferation even though ErbB3 does not possess an active tyrosine kinase domain [10]. ErbB3 phosphorylation activates phosphatidylinositol 3-kinase (PI3K) and its downstream target, Akt, thus providing a possible mechanism for the requirement for both ErbB2 and ErbB3 in stimulating mammary tumourigenesis. This gives rise to the hypothesis that expression of activated Akt could compensate for the expression of ErbB3 in ErbB2-induced mammary tumours.
###end p 12
###begin p 13
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 295 310 <span type="species:ncbi:10090">transgenic mice</span>
###xml 414 429 <span type="species:ncbi:10090">transgenic mice</span>
###xml 636 641 <span type="species:ncbi:10090">mouse</span>
###xml 796 800 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 924 928 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 939 943 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 991 995 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1092 1097 <span type="species:ncbi:9606">human</span>
Our group and others have demonstrated that expression of activated Akt1 [11,12] or overexpression of non-activated Akt1 [13] can delay mammary gland involution. In spite of the fact that Akt was discovered as an oncogene which induces leukaemia [14], mammary tumours were not observed in these transgenic mice [11-13]. Hutchinson et al. demonstrated that activated Akt1 could accelerate mammary tumourigenesis in transgenic mice that express activated ErbB2 [15]. Similarly, deletion of one or both alleles of phosphatase and tensin homolog (PTEN), a negative regulator of Akt signalling, accelerates tumour induction in another ErbB2 mouse mammary tumour model [16]. In the current study, we demonstrate that transgenic expression of activated Akt1 can accelerate mammary tumourigenesis in the MMTV-c-ErbB2 mice. However, we observe a significant attenuation of tyrosine kinase signalling in tumours from the bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 animals compared with tumours from the MMTV-c-ErbB2 animals, particularly with regard to ErbB3 and Src. These results have implications for human ErbB2-positive tumours that may also have high levels of activated Akt, whether due to the loss of the tumour suppressor PTEN or mutations in either PI3K or Akt.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lines
###end title 15
###begin p 16
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 4 8 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
###xml 122 126 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 322 326 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 336 340 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
The MMTV-c-ErbB2 (line 202) transgenic mice [6] were obtained from The Jackson Laboratory, Bar Harbor, ME. Details of the MMTV-myr-Akt1 mice have been previously described [11]. These two FVB-derived transgenic lines were crossed and progeny genotypes were determined by PCR analysis. Virgin MMTV-c-ErbB2 and bitransgenic MMTV-c-ErbB2, MMTV-myr-Akt1 female mice were palpated weekly to detect the presence of mammary tumours starting at 60 days of age. Tumours were excised when they reached 1 cm in diameter and 1 cm deep, and normal, non-tumourigenic mammary tissue was harvested from the same animal at the time of tumour harvest. All mice were maintained in the Center for Comparative Medicine at the University of Colorado Denver - Anshutz Medical Campus, an Association for Assessment and Accrediation of Laboratory Animal Care-approved facility, and used in accordance with Institutional Animal Care and Use Committee-approved protocols.
###end p 16
###begin title 17
Isolation of tail DNA and genotyping by PCR
###end title 17
###begin p 18
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
DNA was extracted from 1.5 cm sections of tail and genotyping was performed using previously described protocols [11]. Detection of the Myr-Akt1 transgene utilised a forward primer which anneals to the Akt1 sequence: (5'-GCCGCTACTATGCCATGAAGA-3') and a reverse primer which anneals to the HA (haemagglutin) epitope: (5'-GTAATCTGGAACATCGTATGGGTA-3'). Detection of the ErbB2 transgene utilised the forward primer (Neu-3) 5'-CGGAACCCACATCAGGCC-3' and the reverse primer (Neu-4) 5'-TTTCCTGCAGCAGCCTACGC-3' [17].
###end p 18
###begin title 19
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Mutation analysis of tumour ERBB2 transgene
###end title 19
###begin p 20
###xml 155 161 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 342 344 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 446 451 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 151 154 <span type="species:ncbi:10116">rat</span>
Total RNA isolated from tumour samples was subjected to single-strand cDNA synthesis using 2.5 muM random hexamers and 1 mug RNA. Amplification of the rat ERBB2 gene, nucleotides 1492 to 2117, was performed using forward primer AB2913, 5'-CGGAACCCACATCAGGCC-3', and reverse primer AB1310, 5'-TTTCCTGCAGCAGCCTACGC-3', as previously described [18]. The PCR products were separated on a 2% agarose gel, the bands of interest (representing truncated ERBB2) were purified and then re-amplified using the same primers. Sequence analysis was conducted by the University of Colorado Cancer Center Sequencing Core using forward primer 1882, 5'-CACTACAAGGACTCGTCCT-3', and reverse primer 2133, 5'-CCAACGACCACCACTAAG-3'.
###end p 20
###begin title 21
Histological analysis and mitotic index quantification
###end title 21
###begin p 22
Dissected tumours and normal mammary tissue were fixed in 4% neutral buffer formalin, embedded in paraffin, sectioned (4 mum) and stained with haematoxylin and eosin. Histological sectioning and staining were performed by the Histology Service, Department of Pathology, University of Colorado School of Medicine. The mitotic index of tumours of each genotype was determined by counting the number of mitotic figures in 10 fields of view with a magnification of 500 and the data were presented as the mean of three tumours +/- standard deviation (SD).
###end p 22
###begin title 23
Quantification of apoptotic cells
###end title 23
###begin p 24
###xml 302 306 <span type="species:ncbi:9925">goat</span>
###xml 526 530 <span type="species:ncbi:9925">goat</span>
###xml 536 542 <span type="species:ncbi:9986">rabbit</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
###xml 861 866 <span type="species:ncbi:10090">mouse</span>
Detection of apoptotic cells was performed by immunohistochemical staining with anti-active caspase-3 antibody (Cell Signaling Technologies, Beverly, MA, USA). For antigen retrieval, slides in citrate buffer were heated in a microwave for 20 minutes and allowed to cool before blocking with 10% normal goat serum. Slides were incubated overnight at 4degreesC with anti-activated caspase-3 antibody at a dilution of 1:100. Non-specific peroxidase activity was quenched with 1% hydrogen peroxide followed by secondary antibody (goat anti-rabbit) then tertiary Vector ABC (Vector Laboratories, Burlingame, CA, USA). Colour development was achieved by incubation with DAB followed by counterstaining with Gill's Haematoxylin. Cell counts were performed on a minimum of five fields of view per slide from three mice (total cells counted ranged from 1800 to 2500 per mouse).
###end p 24
###begin title 25
Immunoblot analysis
###end title 25
###begin p 26
Protein was extracted from frozen tumour tissue and normal tissue by grinding them to a powder under liquid nitrogen, resuspended in Mammary Gland Lysis Buffer (50 mM Tris (2-Amino-2-(hydroxymethyl)-1,3-propanediol) pH 7.4, 150 mM sodium chloride, 2 mM EDTA, 50 mM sodium fluoride, 1% Triton X-100, 1% deoxycholic acid, 0.1% sodium dodecyl sulfate [SDS], 1 mM dithiothreitol, 5 mM sodium orthovanadate, 100 mug/ml phenylmethanesulphonylfluoride and a complete protease inhibitor cocktail (Roche Applied Sciences, Indianapolis, IN, USA)), followed by Dounce homogenisation. Lysates were clarified by centrifugation and protein concentrations determined using the Bradford assay (BioRad, Hercules, CA, USA). Equal amounts of total protein per lane (2 to 50 mug) were resolved on SDS-polyacrylamide gels, transferred to polyvinylidene difluoride (PVDF) membrane (Immobilon-P, Millipore, Bedford, MA, USA) and immunoblotted with the desired antibody.
###end p 26
###begin p 27
###xml 1097 1104 <span type="species:ncbi:9986">rabbits</span>
###xml 1159 1164 <span type="species:ncbi:9606">human</span>
###xml 1165 1170 <span type="species:ncbi:10090">mouse</span>
Anti-HA antibody was obtained from Roche Applied Sciences (Indianapolis, IN, USA). Anti-phospho-ErbB2 (Tyr877), anti-phospho-ErbB3 (Tyr1289), anti-phospho-retinoblastoma (Rb) (Ser780), anti-phospho-Akt (Ser473), anti-phospho-Src (Tyr416), anti-phospho-Gab2 (Tyr452), anti-phospho-Shc (Tyr313), anti-phospho-Shc (Tyr239/240), anti-Akt, anti-p15, anti-p27 and anti-cyclin D1 antibodies were obtained from Cell Signaling Technologies (Beverly, MA, USA). The anti-ErbB2, anti-ErbB3, anti-ErbB4, anti-EGFR, anti-Src, anti-Shc, anti-beta-actin and anti-ERK1 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-phospho-ErbB2 (Tyr1248) was obtained from Abcam (Cambridge, MA, USA). The anti-Rb antibody was obtained from BD Pharmingen (San Jose, CA, USA). The anti-phospho-ERK antibody was obtained from Promega (Madison, WI, USA). The anti-Gab2 polyclonal antibody was generously supplied by Dr. Haihua Gu (University of Colorado, Denver, USA). The glucose transporter 1 (GLUT1) polyclonal antibody was generated by Global Peptide (Fort Collins, CO, USA) by immunising rabbits with a peptide corresponding to the C-terminus of the human/mouse GLUT1 sequence (KTPEELFHPLGADSQV) and affinity purifying the resulting IgG.
###end p 27
###begin title 28
Metabolic profiling of tumours by magnetic resonance spectroscopy
###end title 28
###begin p 29
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 857 859 856 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1026 1027 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1145 1146 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1332 1334 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1369 1370 1368 1369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
Snap-frozen tissues were ground into a powder under liquid nitrogen then homogenised by sonication in chloroform-methanol to precipitate proteins and separate aqueous and lipid-soluble metabolites as described [19]. The lyophilised aqueous and lipid extracts were dissolved in deuterated solvents and analysed using high-resolution 1H-magnetic resonance spectroscopy (MRS) with the Bruker narrow-bore 500 MHz DRX system and an inverse TXI-5-mm probe (Bruker Biospin Inc., Fremont, CA, USA). The following 1H-nuclear magnetic resonance (NMR) parameters with water suppression ('zgpr') were used: 500.12 MHz operating 1H frequency; 40 accumulations; 0 dB power level; 55 dB irradiation power level; 7.5 mus pulse width; 12 ppm spectral width; and 12.8 second repetition time (fully relaxed). An external standard substance, trimethylsilyl propionic-2,2,3,3,-d4 acid ([TMSP] 20 and 50 mM in heavy water) in a thin sealed glass capillary was placed into the NMR tubes during all experiments for metabolite quantification and as a 1H chemical shift reference (at 0 ppm). After performing Fourier transformation, phase and base line corrections, each 1H peak of corresponding metabolites was integrated using 1D WINNMR program (Bruker Biospin Inc., Fremont, CA, USA). The NMR peak assignment was confirmed by two-dimensional NMR spectra [19]. All quantitative data sets from 1H-MRS are reported as mean +/- SD (n = 5 for each group). The p values (from analysis of variance [ANOVA]) below 0.05 were considered as statistically significant.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
###xml 57 61 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 70 85 <span type="species:ncbi:10090">transgenic mice</span>
Activated myr-Akt1 accelerates mammary tumourigenesis in MMTV-c-ErbB2 transgenic mice
###end title 31
###begin p 32
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 33 48 <span type="species:ncbi:10090">transgenic mice</span>
###xml 151 155 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 202 205 <span type="species:ncbi:10116">rat</span>
###xml 391 395 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
We have previously described the transgenic mice that express the activated myr-Akt1 transgene in the mammary gland which rarely develop tumours [11]. MMTV-c-ErbB2 (line 202) mice express the wild type rat ERBB2 gene in the mammary gland and have been an extensively used model of mammary carcinomas [20-22]. To determine whether myr-Akt1 could accelerate mammary tumourigenesis, we crossed MMTV-c-ErbB2 (line 202) mice [6] with MMTV-myr-Akt1 mice [11]. The MMTV-c-ErbB2 female mice developed single focal mammary tumours with a mean latency of 231 days (Figure 1a).
###end p 32
###begin p 33
###xml 175 179 175 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 686 692 686 692 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b-e) </bold>
###xml 1126 1130 1126 1130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1462 1466 1462 1466 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 13 17 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 28 32 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 233 237 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 311 315 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 326 330 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 343 347 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 779 784 <span type="species:ncbi:10090">mouse</span>
###xml 825 829 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 840 844 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 1156 1160 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1171 1175 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1184 1188 <span type="species:ncbi:10090">mice</span>
###xml 1227 1231 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1240 1244 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1548 1552 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1561 1565 <span type="species:ncbi:10090">mice</span>
Bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice have decreased mammary tumour latency, more aggressive tumour histology and decreased apoptosis compared with MMTV-c-ErbB2 mice. (a) Mammary tumour latency in bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice and MMTV-c-ErbB2 mice. Sixty days after birth, bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 and MMTV-c-ErbB2 mice were palpated weekly to monitor for the presence of mammary tumours. The graph shows the rate at which tumours were first detected for both genotypes. A total of 22 bitransgenic mice and 30 MMTV-c-ErbB2 mice were monitored and the graph shows the number of days to tumour detection versus the percentage of tumour-free mice. (b-e) Haematoxylin and eosin stained tumour sections. (b) Tumour derived from a MMTV-c-ErbB2 mouse. (c-e) Tumors derived from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice. (c) A bitransgenic tumour with histology similar to that of c-ErbB2 tumours. (d-e) Two different bitransgenic tumours demonstrating necrotic tumour tissue distal to a blood vessel (blood vessel marked with * and necrosis marker with **). x200 original magnification. (f) Tumours from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice have less apoptosis than tumours from MMTV-c-ErbB2 mice. Apoptosis was quantitated by activated caspase-3 immunohistochemistry. The number of cells staining positively for activated caspase-3 was divided by the total number of cells counted to generate the apoptotic rate. (g) Tumours from bitransgenic mice have a higher proliferation rate than tumours from MMTV-c-ErbB2 mice. Proliferation rate was determined by counting the number of mitotic figures in 10 500x magnification fields of view and the data is presented as the mean +/- standard deviation for three tumours of each genotype.
###end p 33
###begin p 34
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 17 21 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 31 35 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
The bitransgenic MMTV-c-ErbB2, MMTV-myr-Akt1 mice developed single focal mammary tumours with a mean latency of 114 days, meaning the bitransgenic animals develop mammary tumours twice as fast as the MMTV-c-ErbB2 mice (Figure 1a). A total of 30 MMTV-c-ErbB2 mice and 22 bitransgenic mice were used to calculate mean tumour latency.
###end p 34
###begin p 35
###xml 88 96 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-ERBB2 </italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 338 345 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-ERBB2</italic>
###xml 497 505 497 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-ERBB2 </italic>
###xml 23 27 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 84 87 <span type="species:ncbi:10116">rat</span>
###xml 256 260 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 334 337 <span type="species:ncbi:10116">rat</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 493 496 <span type="species:ncbi:10116">rat</span>
Tumours arising in the MMTV-c-ErbB2 mice usually display mutations in the wild type rat c-ERBB2 transgene resulting in a constitutively activated form of ErbB2 [18]. One possible means by which expression of myr-Akt1 could accelerate tumourigenesis in the MMTV-c-ErbB2 mice would be to bypass the apparent requirement for mutation of rat c-ERBB2. However, analysis of the tumours that appeared in the bitransgenic mice indicated that these tumours also contain the activating mutations in the rat c-ERBB2 allele (data not shown).
###end p 35
###begin p 36
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 652 657 652 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d, e</xref>
###xml 722 726 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
Tumour histology was evaluated using haematoxylin and eosin stained sections. The histology of the c-ErbB2 tumours was consistent with previous descriptions: they are solid tumours composed of uniformly sized and shaped cells with small stroma and no evidence of myoepithelial cells [6,23] (Figure 1b). Staining of tumours from the bitransgenic animals revealed two different types of tumours: those similar to c-ErbB2 tumours with a solid, uniform architecture (Figure 1c); and the second type of tumour demonstrated necrosis in areas of the tumour 10 to 20 cells away from vasculature, consistent with a tumour that outgrows its blood supply (Figure 1d, e). Very little necrosis is ever observed in tumours derived from MMTV-c-ErbB2 mice.
###end p 36
###begin p 37
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g</xref>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
###xml 344 348 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 357 372 <span type="species:ncbi:10090">transgenic mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 997 1001 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1185 1189 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
After initial detection, tumour volumes were determined by measuring the tumour dimensions with calipers to estimate tumour volume (volume = (length x width x width)/2). A comparison of tumour growth in mice of both genotypes revealed that tumour volume increased two to three times faster in the bitransgenic mice compared with tumours in the MMTV-c-ErbB2 transgenic mice (data not shown). The increased growth rate of tumours in the bitransgenic mice could result from either increased proliferation, decreased apoptosis or both. Measurement of the apoptotic rates in both tumour types by activated caspase-3 immunohistochemistry demonstrates that the tumours from the bitransgenic animals have an apoptotic rate half that of the tumours derived from the MMTV-c-ErbB2 animals (Figure 1f). The rate of proliferation, determined by quantitating the number of mitotic figures in tumour sections, demonstrated that tumours from bitransgenic animals had a higher proliferation rate than tumours from MMTV-c-ErbB2 animals (Figure 1g). Thus, the bitransgenic animals rapidly develop mammary tumours with a low rate of apoptosis and high rate of proliferation compared with the tumours from MMTV-c-ErbB2 animals, and at least half of these bitransgenic tumours exhibit extensive necrosis.
###end p 37
###begin p 38
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 179 183 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 193 197 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 485 490 <span type="species:ncbi:10090">mouse</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 523 538 <span type="species:ncbi:10090">transgenic mice</span>
The expression of the transgenes was examined at the protein level in tumours (T) and normal mammary gland control (N) taken from tumour-bearing mice of both the MMTV-c-ErbB2 and MMTV-c-ErbB2, MMTV-myr-Akt1 genotypes. Mammary glands from FVB mice and MMTV-myr-Akt1 mice were used as controls. Immunoblotting with an anti-ErbB2 antibody demonstrated that the level of ErbB2 protein was dramatically increased in tumours of both origins compared with normal mammary tissue from the same mouse, from FVB mice or from myr-Akt1 transgenic mice (Figure 2a).
###end p 38
###begin p 39
###xml 686 690 686 690 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 702 706 702 706 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 766 770 766 770 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 797 801 797 801 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 819 823 819 823 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 26 30 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 41 45 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 63 67 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 262 266 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
Tumours from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice and MMTV-c-ErbB2 mice overexpress ErbB2 and phosphorylated Akt. Tumour (T) and normal mammary tissue (N) were harvested from tumour-bearing mice. Tumours from three different bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice and three different MMTV-c-ErbB2 mice are represented with normal mammary tissue from the same animal. Additionally, normal mammary tissue was collected from control FVB and MMTV-myr-Akt1 mice and analysed as a control. Equal amounts of total protein was loaded per lane to a 10% sodium dodecyl sulfate polyacrylamide gel, transferred to polyvinylidene difluoride and probed with the following antibodies: (a) anti-ErbB2; (b) anti-HA to detect the HA epitope-tagged myr-Akt1 transgene; (c) anti-phospho-Akt (Ser473); (d) anti-pan-Akt; and (e) anti-beta-actin to demonstrate equal loading of the gel.
###end p 39
###begin p 40
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d</xref>
###xml 739 741 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
Expression of the HA-tagged myr-Akt1 transgene was only detected in tumour tissue from the bitransgenic animals (Figure 2b). The myr-Akt1 transgene in the bitransgenic tumours was phosphorylated at Ser473, indicating enzymatic activity, and can be distinguished from endogenous Akt because the myr-Akt1 transgene has a higher molecular weight (Figure 2c). Akt was also phosphorylated in c-ErbB2 tumours, consistent with previously published data [8] (Figure 2c). Immunoblot using anti-pan-Akt antibody demonstrates expression of endogenous Akt in both tumour types with the c-ErbB2 tumours expressing more Akt than the bitransgenic tumours (Figure 2d). An immunoblot with anti-beta-actin antibody demonstrates equal sample loading (Figure 2e). All immunoblot data presented in the present study is representative of all tumour and normal gland pairs examined (n = 5 for c-ErbB2 and n = 7 for bitransgenic). The different levels of proteins expressed in tumour tissue versus normal tissue is probably due to both a difference in selective pressures brought on by tumourigenesis and a dramatic increase in epithelial cell content in tumour tissue: the virgin mammary gland is predominantly adipocytes and tumour tissue is predominantly epithelial in nature.
###end p 40
###begin title 41
Diminished overexpression and activation of EGFR family members in tumours from bitransgenic animals
###end title 41
###begin p 42
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 561 566 561 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a, b</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3e</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3g</xref>
###xml 21 36 <span type="species:ncbi:10090">transgenic mice</span>
###xml 243 247 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 972 976 <span type="species:ncbi:10090">mice</span>
Mammary tumours from transgenic mice expressing activated mutants of ErbB2 also express elevated levels of total and tyrosine-phosphorylated ErbB2 and ErbB3 [7]. As previously shown in Figure 2, ErbB2 was increased in tumour lysates from both MMTV-c-ErbB2 and bitransgenic mice compared with normal tissue (Figure 3c). The extent of activating phosphorylation of ErbB2 was lower in the bitransgenic tumours than in the c-ErbB2 tumours, demonstrated by using phosphospecific antibodies to two different phosphorylation sites in ErbB2, Tyr877 and Tyr1248 (Figure 3a, b). Phosphorylation of Tyr877 is mediated by Src and contributes to the activation of the ErbB2 tyrosine kinase, and Tyr1248 is an autophosphorylation site [24,25]. Increased levels of ErbB3 (Figure 3e), Tyr1289-phosphorylated ErbB3 (Figure 3d), epidermal growth factor receptor (EGFR) (Figure 3f) and ErbB4 (Figure 3g) were readily detected in the c-ErbB2 tumours compared with normal tissue from the same mice.
###end p 42
###begin p 43
###xml 314 318 314 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 347 351 347 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 381 385 381 385 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 397 401 397 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 431 435 431 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 447 451 447 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 462 466 462 466 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 482 486 482 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(h) </bold>
###xml 115 119 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 130 134 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
Expression and activation of EGF receptor tyrosine kinase family members is decreased in tumours from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice compared with tumours from MMTV-c-ErbB2 mice. Lysates from tumour (T) and normal mammary tissue (N) were used for immunoblot analysis using the following antibodies: (a) anti-phospho-ErbB2 (Tyr877); (b) anti-phospho-ErbB2 (Tyr1248); (c) anti-ErbB2; (d) anti-phospho-ErbB3 (Tyr1289); (e) anti-ErbB3; (f) anti-EGFR; (g) anti-ErbB4; and (h) anti-beta-actin to demonstrate equal loading of the gel.
###end p 43
###begin p 44
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3g</xref>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 705 709 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 718 733 <span type="species:ncbi:10090">transgenic mice</span>
While increased levels of EGFR and ErbB3 protein could be detected in the bitransgenic tumours when compared with normal tissue, the extent of the increase was dramatically reduced compared with that observed in the c-ErbB2 tumours. Most importantly, the phosphorylation of ErbB3 was very low at Tyr1289 (Figure 3d), which is an important phosphorylation site for PI3K recruitment and activation [26]. ErbB4, the sole member of the EGFR family with an expression that bears positive prognostic value to breast cancer patients and suppresses proliferation and promotes apoptosis [27,28], was not detected in the bitransgenic tumours (Figure 3g). These data suggest that expression of activated Akt1 in the MMTV-c-ErbB2 transgenic mice alters the requirement for overexpression and activation of ErbB3 and other EGFR family members in mammary tumours induced by ErbB2.
###end p 44
###begin title 45
Diminished activation of signalling downstream of ErbB2 in bitransgenic tumours
###end title 45
###begin p 46
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Mammary tumours expressing c-ErbB2 have been found to possess elevated levels of Src tyrosine protein kinase activity [29,30]. The Src protein binds to phosphotyrosine residues in the cytoplasmic tail of ErbB2, resulting in Src phosphorylation at Tyr416 and catalytic activation [31,32]. The amount of Tyr416-phosphorylated Src present in the c-ErbB2 tumours was dramatically increased in comparison to the bitransgenic tumours and normal tissue (Figure 4a), even though the bitransgenic tumours express more total Src than the c-ErbB2 tumours (Figure 4b). The reduced Src activation indicated by low Tyr416 phosphorylation levels in the bitransgenic tumours is corroborated by the reduced phosphorylation of ErbB2 at Tyr877 (Figure 3a), which is mediated by Src [24,25]. The reciprocal positive regulation of Src by ErbB2 and ErbB2 by Src is strongly diminished in the bitransgenic tumours (in addition to the reduced activation of ErbB3) indicating a general decline in plasma membrane tyrosine kinase signalling in the bitransgenic tumours.
###end p 46
###begin p 47
###xml 253 257 253 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 284 288 284 288 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 298 302 298 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 330 334 330 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 345 349 345 349 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 376 380 376 380 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 411 415 411 415 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 425 429 425 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(h) </bold>
###xml 512 516 512 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i) </bold>
###xml 13 17 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 28 32 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Tumours from MMTV-myr-Akt1, MMTV-c-ErbB2 mice have decrease tyrosine kinase signalling compared with tumours from MMTV-c-ErbB2 mice. Lysates from tumour (T) and normal mammary tissue (N) were used for immunoblot analysis using the following antibodies: (a) anti-phospho-Src (Tyr416); (b) anti-Src; (c) anti-phospho-Gab2 (Tyr452); (d) anti-Gab2; (e) anti-phospho-Shc (Tyr313); (f) anti-phospho-Shc (Tyr239/240): (g) anti-Shc; (h) anti-phospho-Erk (corresponding to Erk2 phosphorylation at Thr183 and Tyr185); and (i) anti-Erk.
###end p 47
###begin p 48
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
The lack of activation/overexpression of EGFR family members and the lack of activation of Src in the bitransgenic tumours suggested that signalling mediated by secondary signalling molecules might also be attenuated in the bitransgenic tumours when compared with c-ErbB2 tumours. Gab2 is a scaffolding protein that can recruit the p85 subunit of PI3K when it is phosphorylated at Tyr452 [33] which in turn activates PH-domain containing proteins such as Akt [34]. The levels of Gab2 protein are elevated in both c-ErbB2 tumours and bitransgenic tumours compared with normal gland controls (Figure 4d), although the level is slightly higher in c-ErbB2 tumours than bitransgenic tumours. The amount of Tyr452-phosphorylated Gab2 is dramatically higher in the c-ErbB2 tumours compared with the bitransgenic tumours (Figure 4c) suggesting that expression of activated Akt1 in the bitransgenic animals attenuates phosphorylation of Gab2 and subsequent docking of PI3K, which occurs in c-ErbB2 animals.
###end p 48
###begin p 49
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4g</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4f</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4e</xref>
It has recently been demonstrated that another secondary signalling molecule, ShcA, is required for ErbB2-mediated tumourigenesis and phosphorylation of Tyr313 in ShcA may be important for tumour cell survival, while phosphorylation of Tyr239/240 may be important for tumour vascularisation [35]. c-ErbB2 tumours and bitransgenic tumours both demonstrate expression of ShcA (Figure 4g), particularly the p52 and the p46 isoforms while the p66 isoform was barely detectable. Both tumour types also appear to have similar levels of Tyr239/240-phosphorylated ShcA (with the bitransgenic tumours having slightly less phosphorylation than the c-ErbB2 tumours), indicating that activities regulated by phosphorylation of this site (perhaps in angiogenesis) are important in both tumour types (Figure 4f). However, the difference in phosphorylation of ShcA at Tyr313 is more dramatic between the two tumour types (Figure 4e), with the c-ErbB2 tumours having more ShcA phosphorylated at Tyr313 than the bitransgenic tumours suggesting that activities regulated by phosphorylation of this site (cell survival) may be less important in the tumours that express activated Akt1.
###end p 49
###begin p 50
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4h</xref>
###xml 247 252 <span type="species:ncbi:9606">human</span>
Oncogenic signalling often activates the Erk pathway, which is a known mediator of cell proliferation, cell survival, angiogenesis and cell migration (reviewed in [36]). Dual phosphorylation of Erk1 and Erk2 (corresponding to Thr183 and Tyr185 of human Erk2) in the activation loop results in catalytic activation of kinase activity [37]. Despite the attenuation of several signalling events in the bitransgenic tumours when compared with the c-ErbB2 tumours as discussed above, both tumour types maintain similar levels of phosphorylated/activated Erk (Figure 4h) indicating that transgenic activation of Akt1 does not bypass Erk signalling. Normal gland controls demonstrate various levels of Erk activation.
###end p 50
###begin title 51
Expression/activation of cell cycle control proteins in bitransgenic tumours
###end title 51
###begin p 52
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 922 929 922 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
The decrease in the tumour latency observed in the bitransgenic tumours would predict that there would be a change in the expression/modification of cell cycle control proteins in the bitransgenic tumours compared with the c-ErbB2 tumours. Phosphorylation of Rb by active cyclin-dependent kinases inactivates Rb activity and is an important regulatory step in cell cycle entry [38,39]. Immunoblot analysis with a phospho-specific antibody against Rb (Ser780) demonstrated Rb phosphorylation in tumour lysates from both genotypes of mice and not in the normal tissue from the same mice (Figure 5a). The extent of Rb phosphorylation was greater in the c-ErbB2 tumours than in the bitransgenic tumours. This is surprising because the bitransgenic tumours have a shorter tumour latency and greater mitotic index which we predicted would correlate with more Rb phosphorylation and a more active cell cycle. However, Hutchinson et al. observed a similar phenomenon in their study: the NDL2 tumours (activated ErbB2) demonstrated a higher level of Ser780-phosphorylated Rb than the bitransgenic NDL2/Akt1DD tumours even though the bitransgenic animals had a shorter tumour latency [15]. The total amount of Rb is almost the same in all tumours examined indicating differences observed in Rb phosphorylation are not in fact due to differences in total Rb levels (Figure 5b).
###end p 52
###begin p 53
###xml 248 252 248 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 278 282 278 282 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 291 295 291 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 311 315 311 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 329 333 329 333 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 94 98 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 109 113 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
MMTV-c-ErbB2 tumours demonstrate different cell cycle proteins than tumours from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice. Lysates from tumour (T) and normal mammary tissue (N) were used for immunoblot analysis using the following antibodies: (a) anti-phospho-Rb (Ser780); (b) anti-Rb; (c) anti-cyclin D1; (d) anti-p15; and (e) anti-p27.
###end p 53
###begin p 54
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
We also examined a second cell cycle control protein, cyclin D1. The D-type cyclins are synthesised during the G1 phase of the cell cycle after stimulation of cells with growth factors that stimulate cell cycle entry and are required for cell cycle progression [40]. Immunoblot analysis revealed cyclin D1 in all samples with the bitransgenic tumours having a higher level of cyclin D1 than normal tissue, but the c-ErbB2 tumours containing more cyclin D1 than the bitransgenic tumours (Figure 5c). This data correlates with the Rb phosphorylation data which is consistent with the role of cyclin D1 in positively regulating cyclin dependent kinase activity and phosphorylation of Rb [40].
###end p 54
###begin p 55
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5e</xref>
The bitransgenic tumours have a shorter latency than the c-ErbB2 tumours, but contain less phosphorylated Rb and less cyclin D1, which led us to examine some cell cycle inhibitors. p15 (INK4b), p27 (Kip1) and p21 (Cip1) are all inhibitors of cell cycle progression [41]. Immunoblot analysis for p15 demonstrated high expression in the c-ErbB2 tumours, a lack of expression in all normal glands and very faint expression in the bitransgenic tumours (Figure 5d). The expression profile of p27 was similar with a lack of expression in all normal tissue, high expression in c-ErbB2 tumours and slightly lower level of expression in the bitransgenic tumours (Figure 5e). We were unable to detect p53 and p21 in any of the tumour and normal mammary tissue samples, though both were present in an irradiated control gland (data not shown). While c-ErbB2 tumours contain more positive markers of the cell cycle than the bitransgenic tumours (phosphorylated Rb and cyclin D1), they also express more negative regulators of the cell cycle (p15 and p27), which likely serves to balance cell cycle progression.
###end p 55
###begin title 56
###xml 70 74 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
An elevated metabolic phenotype in bitransgenic tumours compared with MMTV-c-ErbB2 tumours
###end title 56
###begin p 57
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 656 660 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
One of the hallmarks of tumours and tumour cell lines is the elevated level of glucose transport to support the high glycolytic rate of tumour cells [42,43]. Myr-Akt1 can stimulate the translocation of the GLUT1 glucose transporter to the cell surface of lymphoid cells cultured in the absence of growth factors as well as increase hexokinase activity, glucose consumption and lactate production, which suggests that Akt stimulates aerobic glycolysis and produces the so-called 'Warburg effect' [44,45]. Immunoblot analysis demonstrates elevated levels of GLUT1 (the major glucose transporter in cancer cells) in lysates from mammary tumours from both the MMTV-c-ErbB2 and the bitransgenic mice compared with levels in normal glands. However, GLUT1 protein expression was greater in the bitransgenic tumours (Figure 6a). Cell-line transfection using GLUT1 cDNA validates the elongated band identified by GLUT1 immunoblot and the reason for this elongated band is probably due to glycosylation of GLUT1 (data not shown).
###end p 57
###begin p 58
###xml 433 437 433 437 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 463 466 463 466 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 522 526 522 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 538 542 538 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 692 693 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 60 64 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 75 79 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 224 228 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 263 267 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 601 605 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 631 635 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 646 650 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
Metabolic activity is elevated in tumours from bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice compared with tumours from MMTV-c-ErbB2 mice. Increased expression of the GLUT1 glucose transporter in bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 tumours compared with the MMTV-c-ErbB2 tumours. Lysates from tumour (T) and normal mammary tissue (N) were used for immunoblot analysis using a polyclonal antibody against the c-terminus of GLUT1 (a) and actin-loading control (b). Intratumour concentration (nmol/mg tissue) of lactate (c) and glucose (d) in mammary glands at day 2 of lactation (L2), tumours from MMTV-c-ErbB2 and bitransgenic MMTV-myr-Akt1, MMTV-c-ErbB2 mice (all n = 5) calculated from 1H-magnetic resonance spectroscopy.
###end p 58
###begin p 59
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6d</xref>
###xml 690 694 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
To determine whether the increased level of GLUT1 correlated with an increase in glycolysis (increased glucose consumption and increased lactate production), we used MRS to quantitate lactate concentrations in extracts prepared from tumours because lactate is the end product of glycolysis. The mammary tumours examined in this study are of epithelial cell origin, so the use of mammary tissue from day two of lactation (L2) as a control tissue allows for the comparison of normal epithelium with tumour epithelium, whereas the normal virgin mammary gland is composed mostly of adipocytes [46]. Compared with normal L2 tissue, there was a four-fold increase in the amount of lactate in the MMTV-c-ErbB2 tumours and a six-fold increase in the bitransgenic tumours (Figure 6c) (p < 0.00001 between L2 and both tumours and p < 0.02 between ErbB2 and bitransgenic tumours, all n = 5). This increase in tumour glycolytic activity was accompanied by significantly decreased intratumuor concentrations of glucose: 1.10 nmol/mg in the L2 mammary gland, 0.46 nmol/mg in ErbB2 tumours (p < 0.01) and 0.14 nmol/mg in bitransgenic tumours (p < 0.0004) (Figure 6d). This indicates high glucose utilisation due to the increased activity of glycolytic enzymes. Thus, the bitransgenic tumours appear to consume more glucose and secrete more lactate than the c-ErbB2 tumours or the normal epithelial cell-enriched lactating mammary gland.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 127 134 127 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1148 1153 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 62 66 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 293 297 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 306 310 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 705 709 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
We have demonstrated that expression of activated myr-Akt1 in MMTV-c-ErbB2 mice accelerates mammary tumourigenesis. Hutchinson et al. used a similar mammary tumourigenesis model using MMTV-NDL2-5 animals (which express activated ErbB2 in the mammary gland) and compared them with bitransgenic MMTV-NDL2-5, MMTV-Akt1DD animals (which express activated ErbB2 and an activated Akt1 gene that contains phosphomimetic mutations of Ser473 and Thr308) [15]. They found that expression of activated Akt1 accelerated ErbB2-induced tumourigenesis in their NDL2 model. The NDL2/Akt1DD bitransgenic tumours were more differentiated glandular tumours which expressed milk proteins. Expression of activated Akt1 in the MMTV-c-ErbB2 model did not induce more differentiated glandular tumours, but rather accelerated tumour formation often appearing to cause necrosis. Compared with the c-ErbB2 tumours, the bitransgenic tumours demonstrated half the amount of apoptosis and twice the amount of mitosis, suggesting that a decrease of apoptosis and increase in proliferation in the bitransgenic tumours contributed to faster tumour formation. Similar to Hutchinson et al., evaluation of apoptosis by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining revealed almost no apoptotic cells in any of our tissue samples (data not shown), but evaluation of apoptosis by activated caspase-3 immunohistochemistry identified some apoptotic cells.
###end p 61
###begin p 62
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 252 256 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 265 270 <span type="species:ncbi:10090">mouse</span>
###xml 460 464 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
ErbB3, the major EGFR family member that activates the PI3K/Akt pathway [47], is required for ErbB2-induced cancer cell proliferation, transformation and colony formation in vitro[8,48]. There is a functional interaction between ErbB2 and ErbB3 in the MMTV-c-ErbB2 mouse model [8]. Activated Src is important for efficient ErbB2/ErbB3 heterocomplex formation and full activation of the ErbB2 kinase domain [24]. We have demonstrated that tumourigenesis in the MMTV-c-ErbB2 model proceeds with reduced activation of ErbB2, ErbB3, Src, Gab2 and Shc when activated Akt1 is expressed by transgene. Akt is often activated in cancer cells by the activating mutation of PI3K [49], inactivation of PTEN [50] and, a recently demonstrated mechanism, by mutation of Akt itself [51]. Our results demonstrate that Akt activation by any of these means may lead to less dependency on ErbB2/ErbB3 and Src signalling without inhibiting tumourigenesis. It is not clear whether the diminished activation of these signalling molecules reflects a reduced need for them to be activated due to the presence of activated Akt or a negative feedback loop by which activated Akt can suppress activation of ErbB3-dependent signalling.
###end p 62
###begin p 63
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 46 50 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
Two recent reports studying tumourigenesis in MMTV-ErbB2 mice on an Akt1-/- background highlight the importance of Akt1 in ErbB2-induced tumourigenesis [52,53]. Both groups used activated ErbB2 models of tumourigenesis in Akt1-/- and Akt+/+ backgrounds and demonstrated the importance of Akt1 in mediating ErbB2-induced tumourigenesis: mice lacking Akt1 either failed to develop tumours or tumourigenesis was delayed. However, while Akt1 is required for efficient tumour formation in MMTV-ErbB2 mouse models, activation of Akt1 alone is not sufficient for mammary tumourigenesis [11,12] indicating that other pathways downstream of ErbB2 activation are important for tumour formation.
###end p 63
###begin p 64
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4h</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
The Erk pathway is activated in many types of cancer and can be activated by numerous oncogenic signals, including ErbB2 (Figure 4h) [36]. The bitransgenic tumours used in the current study maintained Erk activation (despite the loss of numerous other signalling events), which suggests that Erk signalling is necessary in these tumours. This may be one explanation for why Akt is necessary for ErbB2 tumourigenesis [52,53], but is not sufficient for mammary tumourigenesis [11,12]: activation of Akt alone may fail to activate Erk.
###end p 64
###begin p 65
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
Most tumour cells rely on increased glycolysis, even in the presence of available oxygen (the Warburg effect). It has been shown that p53, HIF-1 (hypoxia inducible factor 1), c-Myc as well as Akt can all upregulate glycolytic enzymes (often through inhibition of the mitochondrial tricarboxylic acid cycle) to trigger increased tumour cell glucose consumption [54]. The increased levels of lactate and reduced concentrations of glucose in both types of tumours in the present study is consistent with an increased glycolytic rate in the tumours, but the bitransgenic tumours contained more lactate and more GLUT1 than the c-ErbB2 tumours. This led to the hypothesis that activation of Akt1 induced aerobic glycolysis in these mammary carcinomas. This may offer another explanation for the accelerated tumour onset in the bitransgenic animals because glycolysis, while inefficient in terms of wasting the full oxidative potential of glucose, is efficient at producing ATP and also generating metabolic byproducts necessary for membrane synthesis [55].
###end p 65
###begin p 66
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 390 397 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 596 603 <span type="species:ncbi:9606">patient</span>
###xml 990 995 <span type="species:ncbi:9606">human</span>
###xml 1300 1308 <span type="species:ncbi:9606">patients</span>
Human breast carcinomas overexpress ErbB2 in 20% to 30% of cases and patients with this type of tumour bear a poor prognosis and are currently treated with trastuzumab, a humanised monoclonal antibody. Trastuzumab treatment significantly boosts the prognosis for patients with breast tumours that overexpress ErbB2, but the response rate for these patients is about 50% to 60% [56]. Nagata et al. demonstrated that loss of the PTEN tumour suppressor (which induces Akt activation) predicts resistance to trastuzumab treatment [57]. We predict that our bitransgenic animals represent a model of a patient who would be resistant to trastuzumab. Tumours from bitransgenic animals overexpress ErbB2, making them candidates for ErbB2-targeted therapy, but drugs which molecularly target ErbB2 (such as trastuzumab) or ErbB2/ErbB3 heterodimers (such as pertuzumab) may be futile because signalling downstream of ErbB2/ErbB3 is already attenuated in bitransgenic animals. If activation of Akt1 in human tumours (which can occur by loss of PTEN function or activating mutation of either PI3K or Akt) is critical to ErbB2-positive breast cancer cells becoming trastuzumab resistant, then evaluation of the activation status of Akt may assist in deciding the prognosis and treatment strategy for breast cancer patients as compared with the current screening that only identifies amplification of ErbB2. Additionally, therapies which molecularly target the Akt pathway may be critical to overcome trastuzumab resistance.
###end p 66
###begin title 67
Conclusion
###end title 67
###begin p 68
###xml 53 57 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Expression of activated Akt1 in the mammary gland of MMTV-c-ErbB2 mice accelerates tumourigenesis and attenuates signalling events sometimes thought to be critical to tumourigenesis. The bitransgenic tumours also have an accelerated glucose metabolism. Our studies suggest that tumours that overexpress ErbB2 which activate Akt by means of mutating PI3K, PTEN or Akt (rather than via ErbB2/ErbB3 activation of PI3K) may be resistant to ErbB2-targeted therapies. Therefore, therapies which molecularly target signalling events downstream of ErbB2, such as those mediated by Akt, may prove to be valuable.
###end p 68
###begin title 69
Abbreviations
###end title 69
###begin p 70
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 396 400 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 403 408 <span type="species:ncbi:10090">mouse</span>
ANOVA = analysis of variance; Akt1DD = constitutively active Akt1 mutant bearing two phospho-mimetic mutations; EGFR = epidermal growth factor receptor; ERK = extracellular-signal regulated kinase; FVB = inbred mouse strain which was exclusively used in this study; Gab2 = Grb2 associated binding protein 2; GLUT1 = glucose transporter 1; L2 = lactation day 2; HIF1 = Hypoxia inducible factor 1; MMTV = mouse mammary tumour virus; MRS = magnetic resonance spectroscopy; Myr-Akt1 = constitutively active Akt1 mutant bearing the myristolation sequence from Src; NMR = nuclear magnetic resonance; PI3K = phosphatidyl inositol-3 kinase; PTEN = phosphatase and tensin homologue deleted on chromosome 10; PVDF = polyvinylidene difluoride; Rb = retinoblastoma; SD = standard deviation; SDS-PAGE = sodium dodecyl sulfate polyacrylamide gel electrophoresis; Shc = Src homology 2 domain-containing transforming protein C1; TMSP = trimethylsilyl propionic-2,2,3,3,-d4 acid.
###end p 70
###begin title 71
Competing interests
###end title 71
###begin p 72
The authors declare that they have no competing interests.
###end p 72
###begin title 73
Authors' contributions
###end title 73
###begin p 74
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
CDY performed the immunoblot analyses, interpreted data, assembled the figures and drafted the manuscript. EN quantitated apoptosis, performed ERBB2 mutation analysis and assisted with preliminary studies. AL maintained the animal colony including breeding, genotyping, tumour palpation and tissue harvest. NJS performed MRS analysis and interpreted metabolic data. SMA conceived the study and directed the research. NJS and SMA critically reviewed the manuscript, which was approved by all authors.
###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
The authors would like to thank Dr Jeff Holt, Dr Ann Thor and Susan Edgerton for consultation on mammary gland and tumour histology. The authors also thank the members of the Mammary Gland Program Project Grant at the University of Colorado Denver for discussions and encouragement during this research. This work was supported by the grants BCTR0600727 from the Susan G. Komen Foundation, P01HD38129 from the Public Health Service to SMA and P30CA046934 Cancer Center Core grant to NJS. CDY is supported by a Predoctoral Fellowship from the US Army Breast Cancer Research Program (BC051149).
###end p 76
###begin article-title 77
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER/neu </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer: correlation of relapse and survival with amplification of the HER/neu oncogene
###end article-title 77
###begin article-title 78
###xml 15 25 15 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER-2/neu </italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
###end article-title 78
###begin article-title 79
###xml 51 66 <span type="species:ncbi:10090">transgenic mice</span>
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
###end article-title 79
###begin article-title 80
Activated neu induces rapid tumor progression
###end article-title 80
###begin article-title 81
###xml 43 58 <span type="species:ncbi:10090">transgenic mice</span>
###xml 72 76 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
###end article-title 81
###begin article-title 82
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
###end article-title 82
###begin article-title 83
###xml 115 130 <span type="species:ncbi:10090">transgenic mice</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
###end article-title 83
###begin article-title 84
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 57 60 <span type="species:ncbi:10116">rat</span>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells
###end article-title 84
###begin article-title 85
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
###end article-title 85
###begin article-title 86
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
###end article-title 86
###begin article-title 87
###xml 56 71 <span type="species:ncbi:10090">transgenic mice</span>
Mammary gland involution is delayed by activated Akt in transgenic mice
###end article-title 87
###begin article-title 88
Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression
###end article-title 88
###begin article-title 89
###xml 36 40 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 46 61 <span type="species:ncbi:10090">transgenic mice</span>
Delayed mammary gland involution in MMTV-AKT1 transgenic mice
###end article-title 89
###begin article-title 90
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">akt</italic>
A retroviral oncogene, akt, encoding a serine threonine kinase containing an SH2-like region
###end article-title 90
###begin article-title 91
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion
###end article-title 91
###begin article-title 92
###xml 102 107 <span type="species:ncbi:10090">mouse</span>
Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis
###end article-title 92
###begin article-title 93
###xml 120 135 <span type="species:ncbi:10090">transgenic mice</span>
Synergistic interaction of the neu proto-oncogene product and transforming growth factor a in the mammary epithelium of transgenic mice
###end article-title 93
###begin article-title 94
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors
###end article-title 94
###begin article-title 95
Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine
###end article-title 95
###begin article-title 96
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
Tyrosine kinase signalling in breast cancer. Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer
###end article-title 96
###begin article-title 97
The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
###end article-title 97
###begin article-title 98
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Mammary gland neoplasia: insights from transgenic mouse models
###end article-title 98
###begin article-title 99
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors
###end article-title 99
###begin article-title 100
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function
###end article-title 100
###begin article-title 101
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
###end article-title 101
###begin article-title 102
Phosphotyrosine interactome of the ErbB-receptor kinase family
###end article-title 102
###begin article-title 103
###xml 82 87 <span type="species:ncbi:9606">human</span>
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells
###end article-title 103
###begin article-title 104
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
###end article-title 104
###begin article-title 105
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway
###end article-title 105
###begin article-title 106
Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity
###end article-title 106
###begin article-title 107
Crystal structures of c-src reveal features of its autoinhibitory mechanism
###end article-title 107
###begin article-title 108
Signal transduction: clamping down on Src activity
###end article-title 108
###begin article-title 109
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
###xml 28 33 <span type="species:ncbi:9606">human</span>
A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners
###end article-title 109
###begin article-title 110
AKT/PKB signaling: navigating downstream
###end article-title 110
###begin article-title 111
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
ShcA signaling is essential for tumour progression in mouse models of human breast cancer
###end article-title 111
###begin article-title 112
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
###end article-title 112
###begin article-title 113
Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase
###end article-title 113
###begin article-title 114
The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression
###end article-title 114
###begin article-title 115
The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
###end article-title 115
###begin article-title 116
Living with or without cyclins and cyclin-dependent kinases
###end article-title 116
###begin article-title 117
Cell cycle control in breast cancer cells
###end article-title 117
###begin article-title 118
Transport of sugars in tumor cell membranes
###end article-title 118
###begin article-title 119
On the origin of cancer cells
###end article-title 119
###begin article-title 120
Akt stimulates aerobic glycolysis in cancer cells
###end article-title 120
###begin article-title 121
Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival
###end article-title 121
###begin article-title 122
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
An atlas of mouse mammary gland development
###end article-title 122
###begin article-title 123
The ErbB signaling network: receptor heterodimerization in development and cancer
###end article-title 123
###begin article-title 124
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
###end article-title 124
###begin article-title 125
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Cancer-specific mutations in PIK3CA are oncogenic in vivo
###end article-title 125
###begin article-title 126
PTEN and cancer
###end article-title 126
###begin article-title 127
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
###end article-title 127
###begin article-title 128
###xml 105 130 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 132 136 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 152 156 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice
###end article-title 128
###begin article-title 129
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Akt1 governs breast cancer progression in vivo
###end article-title 129
###begin article-title 130
Sugar and fat - that's where it's at: metabolic changes in tumors
###end article-title 130
###begin article-title 131
ATP citrate lyase inhibition can suppress tumor cell growth
###end article-title 131
###begin article-title 132
Trastuzumab - mechanism of action and use in clinical practice
###end article-title 132
###begin article-title 133
###xml 116 124 <span type="species:ncbi:9606">patients</span>
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
###end article-title 133

